Skip to main content
Top
Published in: CEN Case Reports 1/2015

01-05-2015

Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon

Authors: Akiko Morisue, Kosuke Fukuoka, Ruiko Goto, Kosuke Ota, Haruhiro Yamashita, Yoko Shinno, Ichiro Yamadori

Published in: CEN Case Reports | Issue 1/2015

Login to get access

Abstract

A 66-year-old, hepatitis C virus (HCV)-positive woman was admitted to our hospital with oliguria, systemic edema, and rapid deterioration of renal function. Laboratory examination showed increased serum creatinine and decreased serum albumin levels, complement activity, and cryoglobulin positivity. The HCV RNA genotype was found to be 1b, and the viral load was high. Kidney biopsy examination showed type I membranoproliferative glomerulonephritis with capillary deposition of IgM and C3, indicating HCV-related glomerulonephritis. After hospitalization, hemodialysis was immediately required because of uremia and oliguria. Her renal function did not improve despite corticosteroid therapy. To treat the increasing HCV load, virus removal and eradication by double-filtration plasmapheresis therapy without interferon was performed, since the patient was allergic to interferon therapy. This treatment improved renal function and allowed the withdrawal from hemodialysis. This report presents a case of successful VRAD without interferon therapy in a patient with HCV-related glomerulonephritis and acute kidney injury that required hemodialysis.
Literature
1.
go back to reference Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–57.CrossRefPubMed Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–57.CrossRefPubMed
2.
go back to reference Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Eng J Med. 1993;328:465–70.CrossRef Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Eng J Med. 1993;328:465–70.CrossRef
3.
go back to reference Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal disease. Clin J Am Soc Nephrol. 2009;4:207–20.CrossRefPubMed Perico N, Cattaneo D, Bikbov B, Remuzzi G. Hepatitis C infection and chronic renal disease. Clin J Am Soc Nephrol. 2009;4:207–20.CrossRefPubMed
4.
go back to reference Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, Mochida S. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37:701–10.CrossRefPubMed Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, Mochida S. Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res. 2007;37:701–10.CrossRefPubMed
5.
go back to reference Namba T, Shiba R, Yamamoto T, et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol. 2010;14:372–6.CrossRefPubMed Namba T, Shiba R, Yamamoto T, et al. Successful treatment of HCV-related cryoglobulinemic glomerulonephritis with double-filtration plasmapheresis and interferon combination therapy. Clin Exp Nephrol. 2010;14:372–6.CrossRefPubMed
6.
go back to reference Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res. 2006;36:167–75.CrossRefPubMed Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, et al. Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res. 2006;36:167–75.CrossRefPubMed
7.
go back to reference Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease. Contrib Nephrol. 2012;176:10–23.PubMed Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease. Contrib Nephrol. 2012;176:10–23.PubMed
8.
go back to reference Kmar N, Rostaing L, Alric L. Treatment of hepatitis C-related glomerulonephritis. Kidney Int. 2006;69:436–9.CrossRef Kmar N, Rostaing L, Alric L. Treatment of hepatitis C-related glomerulonephritis. Kidney Int. 2006;69:436–9.CrossRef
9.
go back to reference Sandri AM, Elewa U, Poterucha JJ, Fervenza FC. Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract. 2011;119:c121–30.CrossRefPubMed Sandri AM, Elewa U, Poterucha JJ, Fervenza FC. Treatment of hepatitis C-mediated glomerular disease. Nephron Clin Pract. 2011;119:c121–30.CrossRefPubMed
10.
go back to reference The Guideline Development Work Group and Evidence Review Team. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Guideline 2: treatment of HCV infection. Kidney Int. 2008;73:S20–45.CrossRef The Guideline Development Work Group and Evidence Review Team. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Guideline 2: treatment of HCV infection. Kidney Int. 2008;73:S20–45.CrossRef
11.
go back to reference Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151–6.PubMed Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol. 1994;89:2151–6.PubMed
12.
go back to reference Fabrizi F, Aqhemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013;84:874–9.CrossRefPubMed Fabrizi F, Aqhemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013;84:874–9.CrossRefPubMed
13.
go back to reference Ahmed MS, Wong CF, Shawki H, Kapoor N, Pandya BK. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type1 associated with hepatitis C treated successfully with steroids and antiviral therapy. Clin Nephrol. 2008;69:298–301.CrossRefPubMed Ahmed MS, Wong CF, Shawki H, Kapoor N, Pandya BK. Rapidly deteriorating renal function with membranoproliferative glomerulonephritis Type1 associated with hepatitis C treated successfully with steroids and antiviral therapy. Clin Nephrol. 2008;69:298–301.CrossRefPubMed
14.
go back to reference Sanai T, Watanabe I, Hirano T, Nakayama M, et al. Successful of steroid treatment in a patient with membranoproliferative glomerulonephritis associated with hepatitis C virus. Int Urol Nephrol. 2009;41:179–83.CrossRefPubMed Sanai T, Watanabe I, Hirano T, Nakayama M, et al. Successful of steroid treatment in a patient with membranoproliferative glomerulonephritis associated with hepatitis C virus. Int Urol Nephrol. 2009;41:179–83.CrossRefPubMed
15.
go back to reference Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84:3336–43.PubMed Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood. 1994;84:3336–43.PubMed
16.
go back to reference Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, Miura AB, Nakamoto Y. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Int Med. 1996;35:529–33.CrossRef Komatsuda A, Imai H, Wakui H, Hamai K, Ohtani H, Kodama T, Oyama Y, Miura AB, Nakamoto Y. Clinicopathological analysis and therapy in hepatitis C virus-associated nephropathy. Int Med. 1996;35:529–33.CrossRef
17.
Metadata
Title
Hepatitis C virus-related glomerulonephritis with acute kidney injury requiring hemodialysis that improved with virus removal and eradication using double-filtration plasmapheresis without interferon
Authors
Akiko Morisue
Kosuke Fukuoka
Ruiko Goto
Kosuke Ota
Haruhiro Yamashita
Yoko Shinno
Ichiro Yamadori
Publication date
01-05-2015
Publisher
Springer Japan
Published in
CEN Case Reports / Issue 1/2015
Electronic ISSN: 2192-4449
DOI
https://doi.org/10.1007/s13730-014-0136-z

Other articles of this Issue 1/2015

CEN Case Reports 1/2015 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.